The looming demise of the de minimis exemption could spur higher costs and delays, said Xeneta’s Niall van de Wouw.

administrator
Related Articles
Food Insecurity Associated With Increased Risk of Post-COVID-19…
- September 17, 2025
FDA Approves Bosaya and Aukelso, Biosimilars to Reference…
- September 17, 2025
Cemiplimab With Chemotherapy Sustains OS at 5 Years…
- September 17, 2025